O-Glcnacylation on LATS2 Disrupts the Hippo Pathway by Inhibiting Its Activity
O-GlcNAcylation on LATS2 disrupts the Hippo pathway by inhibiting its activity Eunah Kima,b, Jeong Gu Kangc, Min Jueng Kangd, Jae Hyung Parke, Yeon Jung Kima,b, Tae Hyun Kweona,b, Han-Woong Leee, Eek‐hoon Jhoa,f, Yong-ho Leea,g, Seung-Il Kimh, Eugene C. Yia,d, Hyun Woo Parke, Won Ho Yanga,i, and Jin Won Choa,b,i,1 aGlycosylation Network Research Center, Yonsei University, 03722 Seoul, Republic of Korea; bInterdisciplinary Program of Integrated OMICS for Biomedical Science, Graduate School, Yonsei University, 03722 Seoul, Republic of Korea; cGenome Editing Research Center, Korea Research Institute of Bioscience and Biotechnology, 34141 Daejeon, Republic of Korea; dDepartment of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, 03080 Seoul, Republic of Korea; eDepartment of Biochemistry, College of Life Science and Biotechnology, Yonsei University, 03722 Seoul, Republic of Korea; fDepartment of Life Science, University of Seoul, 02504 Seoul, Republic of Korea; gDepartment of Internal Medicine, Yonsei University College of Medicine, 03722 Seoul, Republic of Korea; hCollege of Medicine, Yonsei University, 03722 Seoul, Republic of Korea; and iDepartment of Systems Biology, College of Life Science and Biotechnology, Yonsei University, 03722 Seoul, Republic of Korea Edited by John A. Hanover, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD, and accepted by Editorial Board Member Kathryn V. Anderson April 28, 2020 (received for review August 5, 2019) The Hippo pathway controls organ size and tissue homeostasis by autophosphorylation of its activation loop (Ser909 for LAST1 and regulating cell proliferation and apoptosis. The LATS-mediated Ser872 for LATS2) (14, 16).
[Show full text]